- Poster presentation
- Open Access
Prime-boost strategy for vaccine development against both Plasmodium vivax and P. falciparum using MSP-119 as antigen
© Mehrizi et al; licensee BioMed Central Ltd. 2010
- Published: 16 December 2010
- Protective Immunity
- Vaccine Development
- Substantial Level
The present results are encouraging to develop a multispecies human malaria vaccine against asexual blood stage of P. vivax and P. falciparum. Further study is needed to evaluate the protective efficacy of this vaccine in non-human primates.
- Daly TM, Long CA: Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol. 1995, 155: 236-243.PubMedGoogle Scholar
- Near KA, Stowers AW, Jankovic D, Kaslow DC: Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminium hydroxide gel in a murine malaria vaccine model. Infect Immun. 2002, 70: 692-701. 10.1128/IAI.70.2.692-701.2002.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.